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The prevalence of antibodies to Strongyloides stercoralis was 
measured in 0–12-year-olds using a bead-based immunoassay 
before and after ivermectin mass drug administration (MDA) 
for scabies in the Solomon Islands. Seroprevalence was 9.3% be-
fore and 5.1% after MDA (P = .019), demonstrating collateral 
benefits of ivermectin MDA in this setting.
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Strongyloides stercoralis is unique among soil-transmitted hel-
minths (STHs) in its ability to complete its life cycle within the 
human host. S. stercoralis infection is most commonly asympto-
matic but may be associated with eosinophilia, fatigue, diarrhea, 
and occasionally larva currens [1]. People with compromised 
immune systems are at risk of potentially fatal hyperinfection 
syndrome [1]. Albendazole or mebendazole are effective against 
other major STH species and have been incorporated into mass 
drug administration (MDA) programs for public health pur-
poses. However, these drugs have limited efficacy for strongy-
loidiasis, for which ivermectin is the first-line agent.
Ivermectin MDA is used widely to control a number of ne-
glected tropical diseases (NTDs), including lymphatic filariasis, 
onchocerciasis, and most recently, scabies [2, 3], but has so far 
not been adopted for S.  stercoralis control. Given the drug’s 
broad antiparasitic effect, ivermectin MDA may have as a col-
lateral benefit the population-level control of S.  stercoralis. 
Evaluation of S.  stercoralis control has been facilitated by se-
rological assays that detect antibodies against the NIE antigen, 
which is present in infective L3 larvae [4]. These antibodies 
likely indicate current or recent infection [5] and have high 
sensitivity and specificity compared with stool examination [4]. 
The NIE antigen has been adapted for use in the Luminex plat-
form, allowing large-scale screening of populations using dried 
blood spots (DBSs) [6].
In the context of a community-randomized trial evaluating 
the addition of azithromycin to ivermectin-based MDA for 
scabies and impetigo in the Solomon Islands, we measured the 
prevalence of antibody responses to the S.  stercoralis NIE an-
tigen before and after MDA.
METHODS
The trial of MDA for scabies and impetigo has been described 
elsewhere [7]. Briefly, selected communities in Malaita prov-
ince in the Solomon Islands were randomized to MDA with 
open-label ivermectin or ivermectin plus azithromycin. All 
residents of these communities were eligible to participate. 
In both trial arms, all participants were examined for scabies 
and offered a single oral dose of ivermectin (200  μg/kg body 
weight). Persons with a contraindication to ivermectin (preg-
nancy, breastfeeding, or weight <15  kg) were offered topical 
permethrin instead. Those in whom a clinical diagnosis of 
scabies was made at baseline were given a second dose of iver-
mectin 7–14 days later. Written informed consent was obtained 
from adults and from a parent or guardian of each child aged 
under 18  years. Assent was also obtained from children who 
were able to provide it. The study was approved by the London 
School of Hygiene and Tropical Medicine Ethics Committee, 
the Solomon Islands National Health Ethics Committee, and the 
Atoifi Adventist Hospital Ethics Committee. The main trial was 
prospectively registered on clinicaltrials.gov (NCT02775617). 
Centers for Disease Control and Prevention (CDC) staff did 
not interact with study participants or have access to identifying 
information.
For the substudy reported here, we collected DBSs from all 
children aged less than 13 years at the baseline and 12-month 
surveys. We used a fluorescent bead-based assay to test for anti-
bodies against the recombinant NIE antigen [6]. Briefly, serum 
was incubated with microspheres conjugated to NIE, beads 
were washed to remove unbound immunoglobulin (Ig), and 
then bound anti-NIE antibody was detected using biotinylated 
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anti-human IgG + IgG4 antibody followed by streptavidin-
phycoerythrin. Plates were run on a Luminex-200 (Austin, 
TX) and results reported as median fluorescence intensity with 
background subtracted (MFI-BG). We used a receiver op-
erating characteristic curve analysis to determine cutoffs for 
seropositivity.
We conducted a before-and-after analysis to determine the ef-
fect of the MDA on the prevalence of antibodies to S. stercoralis. 
Azithromycin has no known activity against S. stercoralis so we 
combined the 2 trial arms into a single group for analysis. We 
calculated the seroprevalence of S. stercoralis at baseline and at 
12 months and the absolute and relative reduction at 12 months. 
Statistical analysis was conducted in R 3.4.2 (R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
In total, 1291 people (including 553 children aged 
0–12  years) were recruited and offered treatment for sca-
bies at the time of the baseline survey. We collected DBSs 
from 539 of these children, representing more than 97% of 
children enrolled in the trial. At the 12-month follow-up, 
1085 individuals (including 479 children aged 0–12  years) 
were seen, and we collected DBSs from 448 children (94%). 
At baseline, 9.3% of the children were seropositive for anti-
bodies to NIE, with a range across the 6 study communities 
of 2.2% to 14.3% (Table 1). At the 12-month follow-up, the 
overall prevalence had declined to 5.1% with a range across 
the communities of 2.1% to 6.7%. The absolute difference in 
prevalence between baseline and 1 year was 4.2% (95% con-
fidence interval [CI], .7–7.5%) and the relative reduction was 
45% (P = .019). The seroprevalence of antibodies to NIE was 
lower at the follow-up visit than at baseline in all communi-
ties. Decreases were greater among children aged 5 years or 
older who would have received ivermectin, not permethrin, 
for treatment of scabies (Table 1). Neither baseline seroprev-
alence nor the magnitude of change following MDA was 
higher in communities with a higher baseline prevalence of 
scabies, where greater proportions of individuals would have 
received 2 doses of ivermectin.
DISCUSSION
Our study adds to the limited available data on the impact of 
ivermectin MDA on S. stercoralis prevalence. In the Northern 
Territory of Australia, a single round of ivermectin MDA re-
duced S. stercoralis seroprevalence from 21% at baseline to 5% 
at 6 months, and a second MDA at month 12 further reduced 
the seroprevalence to 2% at month 18 [8]. In Ecuador, the prev-
alence of S. stercoralis fell from 6.8% to zero following multiple 
rounds of MDA conducted for the purpose of onchocerciasis 
elimination [9]. Here, we showed that in 6 communities in 
Malaita, Solomon Islands, there was a decrease in seroprev-
alence of anti-NIE antibodies 1  year after a single ivermectin 
MDA conducted for the purpose of scabies control. The overall 
reduction in population seroprevalence was accompanied by 
decreases in the MFI-BG against NIE (Supplementary Table 1). 
The decrease was confined to those aged 5 years or older, who 
were much more likely to have received ivermectin, not per-
methrin, based on the weight cutoff of 15 kg. This strengthens 
the case that it was ivermectin MDA that caused the decrease.
There is no single gold-standard test for diagnosis of 
S.  stercoralis. We used serological markers that correlate well 
with more direct measures of infection and are globally recog-
nized as appropriate tests for both diagnosis and assessing post-
treatment clearance. Had we combined serology with other tests 
such as Kato-Katz or polymerase chain reaction on stool speci-
mens we may have detected more cases. We were, however, con-
sistent in the measurement of exposure at both time points so 
are confident in the relative change observed. As complete sero-
reversion of anti-NIE responses after treatment may take more 
than 1 year [5], and not all anti-NIE–positive individuals sero-
revert after successful treatment [6], it is possible that we have 
underestimated the community-level effect of the intervention. 
Our study was not powered to detect changes in seroprevalence 
in each individual community; although community-level 
Table 1. Strongyloides stercoralis Seroprevalence in Children Aged 0–12 Years Before and After Ivermectin Mass Drug Administration
Baseline Seroprevalence, 
% (n/N)
12-Month Follow-up  
Seroprevalence, % (n/N) Absolute Change, %
Relative 
Change, 
%
Age group     
 Children aged 0–12 years (all participants) 9.3 (50/539) 5.1 (23/448) −4.2* −45.2*
 Children aged 0–4 years 3.2 (9/279) 3.5 (8/225) +0.3 +9
 Children aged 5–12 years 15.8 (41/260) 6.7 (15/223) −9.1** −57.6**
Community     
 1 14.3 (19/133) 5.2 (6/110) −9.1 −36.4
 2 2.2 (2/90) 2.1 (2/94) −0.1 −4.5
 3 11.4 (8/70) 6.9 (5/72) −4.5 −60.5
 4 9.0 (13/144) 6.7 (7/105) −2.3 −25.6
 5 7.8 (8/102) 4.9 (3/61) −2.9 −37.2
*P < .05. **P < .01.
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changes were not statistically significant, there were declines in 
seroprevalence in every community, consistent with our overall 
study finding. It is possible some individuals were reinfected be-
tween initial curative treatment at baseline and the 12-month 
survey. However even if reinfection did occur in some subjects, 
this does not negate the substantial overall population-level 
reduction seen.
Data on the prevalence and distribution of STHs in the 
Solomon Islands are limited. Two previous studies showed that 
hookworm, whipworm, and roundworm are common [10]. 
The baseline seroprevalence of S.  stercoralis in children aged 
0–12 years in the current study was 9.3%, which is broadly similar 
to the prevalence of other STH species reported in the Solomon 
Islands [10]. Current national deworming guidelines for the 
Solomon Islands are based on MDA of albendazole, which is 
likely to have little or no impact on S. stercoralis, and there is no 
routine access to diagnostics or treatment for Strongyloides na-
tionally. Integrated strategies combining albendazole with iver-
mectin may therefore be beneficial for control of S. stercoralis 
as well as providing enhanced effectiveness against several STH 
species and allowing simultaneous control of scabies, which is 
highly endemic in the region [3, 7]. The current requirement for 
2 doses of ivermectin, 1 week apart, for scabies MDA may rep-
resent a logistical barrier to integration as single-dose treatment 
is effective against S. stercoralis [11]. Newer antiparasitic drugs 
such as moxidectin show promise as single-dose treatment for 
scabies, strongyloidiasis, and other STHs [12, 13].
We have demonstrated that S.  stercoralis is endemic in the 
Solomon Islands and added to the limited data demonstrating 
that ivermectin MDA, here conducted for the purpose of sca-
bies control, can also reduce S. stercoralis seroprevalence. These 
data highlight ancillary benefits that can be conferred by NTD 
control programs and suggest that STH programs in this re-
gion may benefit from the addition of ivermectin alongside 
albendazole.
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